Comparative study on the inhibition of plasmin and delta-plasmin via benzamidine derivatives

Biochemical and Biophysical Research Communications

Volumn 457, Issue 3, 2015, Pages 358-362

  Alves, Nathan J ^a   Kline, Jeffrey A ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Benzamidine; Delta plasmin; Drug delivery; Fibrinolytic; Inhibitors; Nanoparticle; Plasmin; Tunable

Indexed keywords

4 AMINOBENZAMIDINE; BENZAMIDINE DERIVATIVE; DELTA PLASMIN; PARA AMINOMETHYL BENZAMIDINE; PARA CARBOXYBENZAMIDINE; PENTAMIDINE; PLASMIN; UNCLASSIFIED DRUG; ANTIFIBRINOLYTIC AGENT; MUTANT PROTEIN; PLASMINOGEN; RECOMBINANT PROTEIN;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING SITE; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; INHIBITION CONSTANT; KRINGLE DOMAIN; LIMIT OF QUANTITATION; PRIORITY JOURNAL; WILD TYPE; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; KINETICS; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANTIFIBRINOLYTIC AGENTS; BENZAMIDINES; FIBRINOLYSIN; HUMANS; KINETICS; MODELS, MOLECULAR; MUTANT PROTEINS; PLASMINOGEN; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84922742841     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2014.12.117     Document Type: Article

References (22)

1. S.L. Murphy, J. Xu, K.D. Kochanek, Deaths: final data for 2010. National vital statistics reports : from the centers for disease control and prevention, National Center for Health Statistics, Natl. Vital Stat. Syst. 61 (2013) 1-117.
2. K. Ouriel, E.L. Welch, C.K. Shortell, K. Geary, W.M. Fiore, C. Cimino, Comparison of streptokinase, urokinase, and recombinant tissue-plasminogen activator in an in-vitro model of venous thrombolysis, J. Vasc. Surg. 22 (1995) 593-597.
3. R. Fears, M.J. Hibbs, R.A.G. Smith, Kinetic-studies on the interaction of streptokinase and other plasminogen activators with plasminogen and fibrin, Biochem. J. 229 (1985) 555-558.
4. L. Medved, W. Nieuwenhuizen, Molecular mechanisms of initiation of fibrinolysis by fibrin, Thromb. Haemost. 89 (2003) 409-419.
5. R.H.P. Law, T. Caradoc-Davies, N. Cowieson, A.J. Horvath, A.J. Quek, J.A. Encarnacao, D. Steer, A. Cowan, Q. Zhang, B.G.C. Lu, R.N. Pike, A.I. Smith, P.B. Coughlin, J.C. Whisstock, The X-ray crystal structure of full-length human plasminogen, Cell Reports 1 (2012) 185-190.
6. M.A. Lucas, L.J. Fretto, P.A. Mckee, The binding of human-plasminogen to fibrin and fibrinogen, J. Biol. Chem. 258 (1983) 4249-4256.
7. V.V. Novokhatny, Y.V. Matsuka, S.A. Kudinov, Analysis of ligand-binding to kringles-4 and kringles-5 fragments from human-plasminogen, Thromb. Res. 53 (1989) 243-252.
8. S.G. Mccance, N. Menhart, F.J. Castellino, Amino-acid-residues of the kringle-4 and kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands, J. Biol. Chem. 269 (1994) 32405-32410.
9. P.K. Anonick, B.B. Wolf, S.L. Gonias, Regulation of plasmin, miniplasmin, and streptokinase-plasmin complex by alpha-2-antiplasmin, alpha-2-macroglobulin, and antithrombin-iii in the presence of heparin, Thromb. Res. 59 (1990) 449-462.
10. H.S. Cummings, F.J. Castellino, Interaction of human plasmin with human alpha-2-macroglobulin, Biochemistry (N.Y.) 23 (1984) 105-111.
11. T. Enden, Y. Haig, N. Klow, C. Slagsvold, L. Sandvik, W. Ghanima, G. Hafsahl, P.A. Holme, L.O. Holmen, A.M. Njaastad, G. Sandbaek, P.M. Sandset, CaVenT study Grp. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial, Lancet 379 (2012) 31-38.
12. V.J. Marder, V. Novokhatny, Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential, Thromb. Haemost. 8 (2010) 433-444.
13. V.J. Marder, S. Manyak, T. Gruber, A. Goyal, G. Moreno, J. Hunt, J. Bromirski, P. Scuderi, S.R. Petteway Jr., V. Novokhatny, Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2e 5, Thromb. Haemost. 104 (2010) 780-787.
14. V.J. Marder, A.J. Comerota, R.D. Shlansky-Goldberg, J.P. Davis, C. Deng, K. Hanna, D. Fineberg, Safety of catheter-delivered plasmin in patients with acute lower extremity arterial or bypass graft occlusion: phase I results, Thromb. Haemost. 10 (2012) 985-991.
15. F. Markward, H. Landmann, P. Walsmann, Comparative studies on inhibition of trypsin, plasmin and thrombin by derivatives of benzylamine and benzamidine, Eur. J. Biochem. 6 (1968) 502.
16. J.A. Hunt, S.R. Petteway Jr., P. Scuderi, V. Novokhatny, Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin, Thromb. Haemost. 100 (2008) 413-419.
17. S.A. Evans, S.T. Olson, J.D. Shore, Para-aminobenzamidine as a fluorescentprobe for the active-site of serine proteases, J. Biol. Chem. 257 (1982) 3014-3017.
18. G. Schmer, Purification of bovine thrombin by affinity chromatography on benzamidine-agarose, H-S Z Physiol. Chem. 353 (1972) 810.
19. A.Z. Budzynski, Chromogenic substrates in coagulation and fibrinolytic assays, Lab. Med. 32 (2001) 365-368.
20. A. Cornish-Bowden, A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors, Biochem. J. 137.1 (1974) 143-144.
21. M.J. Cloninger, B. Bilgicer, L. Li, S.L. Mangold, S.T. Phillips, M.L. Wolfenden, Multivalency, in: Anonymous Supramolecular Chemistry, John Wiley & Sons, Ltd, 2012, pp. 95-115.
22. V.M. Krishnamurthy, L.A. Estroff, G.M. Whitesides, Multivalency in ligand design, in: W. Jahnke, D.A. Erlanson (Eds.), Fragment-based Approaches in Drug Discovery, Wiley-VCH, Weinheim, 2006, pp. 11-53.